華測導航(300627.SZ):擬將募投項目結項並將剩餘募資用於永久補充流動資金
格隆匯7月1日丨華測導航(300627.SZ)公佈,公司於2024年7月1日召開了第四屆董事會第七次會議和第四屆監事會第七次會議,審議通過了關於《募投項目結項並將剩餘募集資金用於永久補充流動資金》的議案,同意公司將“北斗高精度基礎器件及終端裝備產能建設項目”“智能時空信息技術研發中心建設項目”“補充流動資金”(以下合稱“本次募投項目”)結項,公司擬將節餘募集資金(含理財及利息收入淨額)合計60,013,624.88元用於永久補充流動資金(具體金額以資金轉出當日銀行結息後專户資金餘額為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.